Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma : a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. / Henriksen, Daniel P; Bodtger, Uffe; Sidenius, Kirsten; Maltbaek, Niels; Pedersen, Lars; Madsen, Hanne; Andersson, Ehm A; Norgaard, Ole; Madsen, Louise K; Chawes, Bo L.
I: Allergy, Asthma and Clinical Immunology, Bind 16, 49, 2020.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma
T2 - a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma
AU - Henriksen, Daniel P
AU - Bodtger, Uffe
AU - Sidenius, Kirsten
AU - Maltbaek, Niels
AU - Pedersen, Lars
AU - Madsen, Hanne
AU - Andersson, Ehm A
AU - Norgaard, Ole
AU - Madsen, Louise K
AU - Chawes, Bo L
N1 - © The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - Background: Omalizumab is approved for treating severe allergic asthma from age 6, but the definition of severe asthma including a systematic assessment to rule out difficult-to-treat asthma has changed since the drug was approved in 2003.Methods: We conducted a systematic review and meta-analysis of two critical (exacerbation rate, oral corticosteroid (OCS) treatment) and eight important clinical outcomes in children, adolescents and adults, and specifically searched papers for systematic assessment of severe asthma.Results: Adults: seven studies (n = 2159) ascertaining exacerbation rate showing a 37% (95% CI 21-50) reduction in favor of omalizumab, larger than the pre-specified minimal clinically important difference (MCID) of 25%. Only one open-label study (n = 82) was identified assessing the percentage of patients experiencing reduction of OCS-maintenance treatment showing a significantly greater decrease in the omalizumab group (- 45% vs. + 18.3%, p = 0.002). Children and adolescents: four studies (n = 1551) reported data on exacerbations (no meta-analysis conducted), showed overall improvements in exacerbation rate and some passed MCID. No OCS studies were identified. No included studies provided systematic assessment of severe asthma according to current guidelines.Conclusions: Omalizumab provides clinically relevant improvements in exacerbation rate among children, adolescents, and adults and in OCS-reduction among adults. New studies incorporating a guideline-approached definition of severe asthma are warranted.
AB - Background: Omalizumab is approved for treating severe allergic asthma from age 6, but the definition of severe asthma including a systematic assessment to rule out difficult-to-treat asthma has changed since the drug was approved in 2003.Methods: We conducted a systematic review and meta-analysis of two critical (exacerbation rate, oral corticosteroid (OCS) treatment) and eight important clinical outcomes in children, adolescents and adults, and specifically searched papers for systematic assessment of severe asthma.Results: Adults: seven studies (n = 2159) ascertaining exacerbation rate showing a 37% (95% CI 21-50) reduction in favor of omalizumab, larger than the pre-specified minimal clinically important difference (MCID) of 25%. Only one open-label study (n = 82) was identified assessing the percentage of patients experiencing reduction of OCS-maintenance treatment showing a significantly greater decrease in the omalizumab group (- 45% vs. + 18.3%, p = 0.002). Children and adolescents: four studies (n = 1551) reported data on exacerbations (no meta-analysis conducted), showed overall improvements in exacerbation rate and some passed MCID. No OCS studies were identified. No included studies provided systematic assessment of severe asthma according to current guidelines.Conclusions: Omalizumab provides clinically relevant improvements in exacerbation rate among children, adolescents, and adults and in OCS-reduction among adults. New studies incorporating a guideline-approached definition of severe asthma are warranted.
U2 - 10.1186/s13223-020-00442-0
DO - 10.1186/s13223-020-00442-0
M3 - Review
C2 - 32565844
VL - 16
JO - Allergy, Asthma and Clinical Immunology
JF - Allergy, Asthma and Clinical Immunology
SN - 1710-1484
M1 - 49
ER -
ID: 260762449